- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Launch of new Nanomedicine journal is no small feat
Posted on June 27, 2006
Future Medicine Ltd (www.futuremedicine.com) is delighted to announce the launch of its latest peer-reviewed title, Nanomedicine (ISSN 1743-5889), which will appear bimonthly from June 2006, and features an acclaimed editorial board of international experts.
“Nanomedicine is emerging as one of the most important sub-disciplines under the nanotechnology umbrella,” says Professor Charles R Martin, Director of the Center for Research at the Bio/Nano Interface and Colonel Allen R and Margaret G Crow Professor of Chemistry, University of Florida (FL, USA), and Senior Editor of the new journal. He continued: “The extraordinarily rapid pace at which this field is advancing, clearly justifies the need for a journal devoted specifically to nanomedicine.”
Nanomedicine will cover the emerging scientific specialty born from nanotechnology, which has grown up in the fields of engineering, physics, chemistry and biotechnology, and is now moving into medicine, with huge potential for expansion and development over the next decade and beyond. The journal promises to be uniquely medicine-focused, addressing the important challenges and advances in medical nanoscale-structured material and devices, biotechnology devices and molecular machine systems and nanorobotics, delivering this essential information in concise, clear and attractive article formats, including reviews, primary research articles, technology reports, perspectives and editorials.
“Our commitment is to attract the interest of the clinicians that eventually will be the end users of all the nanomedicine knowledge and technology generated,” says Kostas Kostarelos, Centre for Drug Delivery Research, University of London (UK) and also Senior Editor of the new journal. Topics covered will include basic research and theoretical applications, benefits of nanotechnology over traditional techniques, potential medical applications and therapeutic applications of nanotechnology advances, nanomedical tools in gene therapy, drug delivery and commercialization, funding, economics and ethics of nanomedical technology.
The Senior Editors and Future Medicine Ltd aim to make - Nanomedicine the main forum in which the challenges and advances in nanotechnology research related to medicine are addressed. In upcoming years, the field promises much Nanomedicine will be there to highlight the main advances and therapeutic possibilities for clinicians and researchers alike and will provide an avenue for debate of controversial issues.
About Future Science Group Ltd:
Future Science Group Ltd, based in London has developed an innovative publishing portfolio to reflect post-genomic medicine. The sequencing of the human genome was a colossal milestone in the evolution of healthcare, with repercussions for all those involved in the healthcare chain. Through its imprints, Future Medicine and Future Drugs, Future Science Group Ltd provides healthcare practitioners and research professionals with a unique source of objective, cutting-edge information on exciting trends emerging in the light of these advances. Our flagship title Pharmacogenomics has evolved to become a leading source of commentary and analysis from international opinion leaders. Momentum toward an individualized approach to medicine is increasing as the value of linking diagnostic and therapeutic approaches becomes ever clearer.
Future Science Group
T: +44 (0) 20 8349 2033
F: +44 (0) 20 8343 2313
Copyright © Future Medicine Ltd
If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Graphenea celebrates fifth anniversary April 27th, 2015